Pneumococcal infectious disease

This phase II trial tests a new 24-valent pneumococcal conjugate vaccine (PCV24) in 992 adults aged 18 and older. The study aims to check the vaccine's safety and how well it triggers an immune response compared to an existing 23-valent vaccine. Participants receive one dose of e…

This early-stage trial is testing a new vaccine called PCV24, designed to protect children against 24 types of pneumococcal bacteria. The study involves 230 healthy children aged 6 weeks to 17 years and will check for side effects and measure immune response. The vaccine is given…

This study tests a new vaccine (RZ700) designed to protect infants and young children against 24 types of pneumococcal bacteria, which can cause pneumonia, meningitis, and ear infections. About 480 healthy children aged 6 weeks to 71 months will receive the vaccine to see if it t…

This study tested a new 24-valent pneumococcal conjugate vaccine (PCV24) in 385 healthy adults aged 18 and older. The goal was to check its safety and how well it triggers an immune response compared to an existing vaccine. Participants received one dose of either a low, middle, …

This completed phase 1b trial tested a new 13-valent pneumococcal conjugate vaccine (PCV13) in 140 healthy infants (2 months old) and children (2-5 years). The goal was to check safety and immune response compared to an existing vaccine. Researchers monitored side effects and ant…

This early-stage trial tested a new 24-valent pneumococcal conjugate vaccine in 119 healthy children aged 2 to 17. The goal was to see if the vaccine is safe and helps the body build immunity against pneumococcal bacteria, which can cause pneumonia and other serious infections. R…